vTv Therapeutics (VTVT) Non-Current Debt (2014 - 2023)
vTv Therapeutics (VTVT) posted Non-Current Debt of $191000.0 for Q4 2023, down 79.28% sequentially from $922000.0 in Q1 2023, and down 14.73% YoY from $224000.0 in Q4 2022.
vTv Therapeutics (VTVT) Non-Current Debt (2014 - 2023) Analysis & Trends
vTv Therapeutics has reported Non-Current Debt for 10 years, with the latest figure at $191000.0 in Q4 2023.
- Quarterly Non-Current Debt fell 14.73% year-over-year to $191000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $191000.0 (down 14.73% YoY) and the FY2023 annual result came in at $191000.0, down 14.73% from the prior year.
- Non-Current Debt eased to $191000.0 in Q4 2023 per VTVT's latest filing, from $922000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $4.5 million in Q1 2021 and troughed at $191000.0 in Q4 2023.
- A 5-year average of $2.0 million and a median of $1.8 million in 2019 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2019 and 2020: Non-Current Debt slumped 88.43% in 2019, then surged 99.19% in 2020.
- Over 5 years, Non-Current Debt stood at $2.6 million in 2019, then increased by 10.38% to $2.9 million in 2020, then slumped by 56.04% to $1.3 million in 2021, then sank by 82.25% to $224000.0 in 2022, then slipped by 14.73% to $191000.0 in 2023.
- According to Business Quant data, Non-Current Debt over the past three periods registered $191000.0, $922000.0, and $224000.0 for Q4 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | vTv Therapeutics | 373.77 Mn | 373.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 191,000.00 |
| Mar 31, 2023 | 922,000.00 |
| Dec 31, 2022 | 224,000.00 |
| Sep 30, 2022 | 1.41 Mn |
| Jun 30, 2022 | 717,000.00 |
| Mar 31, 2022 | 770,000.00 |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 2.26 Mn |
| Jun 30, 2021 | 3.59 Mn |
| Mar 31, 2021 | 4.52 Mn |
| Dec 31, 2020 | 2.87 Mn |
| Sep 30, 2020 | 2.72 Mn |
| Jun 30, 2020 | 3.53 Mn |
| Mar 31, 2020 | 2.96 Mn |
| Dec 31, 2019 | 2.60 Mn |
| Sep 30, 2019 | 1.36 Mn |
| Jun 30, 2019 | 2.19 Mn |
| Mar 31, 2019 | 1.52 Mn |
| Dec 31, 2018 | 6.33 Mn |
| Sep 30, 2018 | 8.61 Mn |